Literature DB >> 8934222

A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome.

K J Fisher1, W M Kelley, J F Burda, J M Wilson.   

Abstract

Adenovirus and adeno-associated virus (AAV) are eukaryotic DNA viruses being developed as vectors for human gene therapy. The strengths of each system have been exploited in a novel vector that is based on an adenovirus-AAV hybrid virus incorporated into a plasmid-based molecular conjugate. Efficient rescue and replication of the recombinant AAV genome in this hybrid required transient expression of rep. This feature was incorporated into the transducing particle by conjugating a rep expression plasmid to the hybrid virus through a polylysine bridge. The resulting particle is an attractive vehicle for gene therapy because it is easily manufactured and capable of efficiently transducing cells with the end result being rescue and replication of the recombinant AAV genome. This particle is also useful in the production of recombinant AAV resulting in yields 10-fold greater than that achieved with transfection-based protocols.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8934222     DOI: 10.1089/hum.1996.7.17-2079

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  22 in total

1.  Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina.

Authors:  J Bennett; A M Maguire; A V Cideciyan; M Schnell; E Glover; V Anand; T S Aleman; N Chirmule; A R Gupta; Y Huang; G P Gao; W C Nyberg; J Tazelaar; J Hughes; J M Wilson; S G Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes.

Authors:  A Lieber; D S Steinwaerder; C A Carlson; M A Kay
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

3.  Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector.

Authors:  A Recchia; R J Parks; S Lamartina; C Toniatti; L Pieroni; F Palombo; G Ciliberto; F L Graham; R Cortese; N La Monica; S Colloca
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 4.  Virus-based gene delivery systems.

Authors:  Cathryn Mah; Barry J Byrne; Terence R Flotte
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Identification of an adeno-associated virus Rep protein binding site in the adenovirus E2a promoter.

Authors:  John M Casper; Jennifer M Timpe; John David Dignam; James P Trempe
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Annu Rev Virol       Date:  2019-07-05       Impact factor: 10.431

Review 8.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

9.  Efficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates.

Authors:  Aurélie Moreau; Rita Vicente; Laurence Dubreil; Oumeya Adjali; Guillaume Podevin; Chantal Jacquet; Jack Yves Deschamps; David Klatzmann; Yan Cherel; Naomi Taylor; Philippe Moullier; Valérie S Zimmermann
Journal:  Mol Ther       Date:  2008-12-16       Impact factor: 11.454

10.  Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors.

Authors:  N Inoue; D W Russell
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.